Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1

Expert Opinion on Investigational Drugs

Volumn 15, Issue 5, 2006, Pages 465-478

  Debnath, Asim K ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

C terminal heptad repeat; Fusion; gp41; Heptad repeats; HIV 1 inhibitor; N terminal heptad repeat; Prefusion

Indexed keywords

ADS J 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DARUNAVIR; DP 107; DP 180; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; LOPINAVIR PLUS RITONAVIR; NB 2; NB 64; NICOBOXIL; PEPTIDE DERIVATIVE; RITONAVIR; SJ 2176; T 1249; THEAFLAVIN 3,3' DIGALLATE; TIPRANAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 33646459953     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.5.465     Document Type: Review

References (58)

1. GALLO RC, MONTAGNIER L: The discovery of HIV as the cause of AIDS. N. Engl. J. Med. (2003) 349:2283-2285.
2. RUSCONI S, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: New advances in HIV entry inhibitors development. Curr. Drug Targets Infect. Disord. (2004) 4:339-355.
3. SANTORO F, VASSENA L, LUSSO P: Chemokine receptors as new molecular targets for antiviral therapy. New Microbiol. (2004) 27:17-29.
4. LIU S, JIANG S: High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr. Pharm. Des. (2004) 10:1827-1843.
5. ROOT MJ, STEGER HK: HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. Des. (2004) 10:1805-1825.
6. MEANWELL NA, KADOW JF: Inhibitors of the entry of HIV into host cells. Curr. Opin. Drug Discov. Devel. (2003) 6:451-461.
7. ESTE JA: Virus entry as a target for anti-HIV intervention. Curr. Med. Chem. (2003) 10:1617-1632.
8. DE CLERCQ E: New developments in anti-HIV chemotherapy. Biochim. Biophys. Acta (2002) 1587:258-275.
9. JIANG S, DEBNATH AK: Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41. Biochem. Biophys. Res. Commun. (2000) 269:641-646.
10. JIANG S, ZHAO Q, DEBNATH AK: Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des. (2002) 8:563-580.
11. ECKERT DM, KIM PS: Mechanisms of viral membrane fusion and its inhibition. Ann. Rev. Biochem. (2001) 70:777-810.
12. WILD C, OAS T, McDANAL C, BOLOGNESI D, MATTHEWS T: A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA (1992) 89:10537-10541.
13. WILD C, DUBAY JW, GREENWELL T et al.: Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA (1994) 91:12676-12680.
14. JIANG S, LIN K, STRICK N, NEURATH AR: HIV-1 inhibition by a peptide. Nature (1993) 365:113.
15. JIANG S, LIN K, STRICK N, NEURATH AR: Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem. Biophys. Res. Commun. (1993) 195:533-538.
16. JIANG S, LIN K: Effect of amino acid replacements, additions and deletions on the antiviral activity of a peptide derived from the HIV-1 GP41 sequence. Pept. Res. (1995) 8:345-348.
17. WILD C, GREENWELL T, MATTHEWS T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retrov. (1993) 9:1051-1053.
18. KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4:1302-1307.
19. KILBY JM, LALEZARI JP, ERON JJ et al.: The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retrov. (2002) 18:685-693.
20. NAGASHIMA KA, THOMPSON DA, ROSENFIELD SI, MADDON PJ, DRAGIC T, OLSON WC: Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. (2001) 183:1121-1125.
21. TREMBLAY CL, KOLLMANN C, GIGUEL F, CHOU TC, HIRSCH MS: Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J. Acquir. Immune Defic. Syndr. (2000) 25:99-102.
22. TREMBLAY CL, GIGUEL F, KOLLMANN C et al.: Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. (2002) 46:1336-1339.
23. LABONTE J, LEBBOS J, KIRKPATRICK P: Enfuvirtide. Nat. Rev. Drug Discov. (2003) 2:345-346.
24. LU M, BLACKLOW SC, KIM PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. (1995) 2:1075-1082.
25. LU M, KIM PS: A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. (1997) 15:465-471.
26. TAN K, LIU J, WANG J, SHEN S, LU M: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA (1997) 94:12303-12308.
27. SHU W, LIU J, JI H, RADIGEN L, JIANG S, LU M: Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry (2000) 39:1634-1642.
28. CHAN DC, CHUTKOWSKI CT, KIM PS: Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA (1998) 95:15613-15617.
29. HERSKOWITZ I: Functional inactivation of genes by dominant negative mutations. Nature (1987) 329:219-222.
30. OTAKA A, NAKAMURA M, NAMEKI D et al.: Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl. (2002) 41:2937-2940.
31. GUSTCHINA E, HUMMER G, BEWLEY CA, CLORE GM: Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. J. Med. Chem. (2005) 48:3036-3044.
32. SIA SK, CARR PA, COCHRAN AG, MALASHKEVICH VN, KIM PS: Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA (2002) 99:14664-14669.
33. JUDICE JK, TOM JY, HUANG W et al.: Inhibition of HIV type 1 infectivity by constrained α-helical peptides: implications for the viral fusion mechanism. Proc. Natl. Acad. Sci. USA (1997) 94:13426-13430.
34. JIN BS, RYU JR, AHN K, YU YG: Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retrov. (2000) 16:1797-1804.
35. SEO JK, KIM HK, LEE TY, HAHM KS, KIM KL, LEE MK: Stronger anti-HIV-1 activity of C-peptide derived from HIV-189.6 gp41 C-terminal heptad repeated sequence. Peptides (2005) 26:2175-2181.
36. ECKERT DM, KIM PS: Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. USA (2001) 98:11187-11192.
37. ECKERT DM, MALASHKEVICH VN, KIM PS: Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J. Mol. Biol. (1998) 284:859-865.
38. SUZUKI K, HIROAKI H, KOHDA D, TANAKA T. An isoleucine zipper peptide forms a native-like triple stranded coiled coil in solution. Protein Eng. (1998) 11:1051-1055.
39. BIANCHI E, FINOTTO M, INGALLINELLA P et al.: Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. USA (2005) 102:12903-12908.
40. BEWLEY CA, LOUIS JM, GHIRLANDO R, CLORE GM: Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. (2002) 277:14238-14245.
41. LOUIS JM, NESHEIWAT I, CHANG L, CLORE GM, BEWLEY CA: Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol. Chem. (2003) 278:20278-20285.
42. ROOT MJ, KAY MS, KIM PS: Protein design of an HIV entry inhibitor. Science (2001) 291:884-888.
43. NI L, GAO GF, TIEN P: Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. Biochem. Biophys. Res. Commun. (2005) 332:831-836.
44. CCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. (2001) 276:29485-29489.
45. CHAN DC, FASS D, BERGER JM, KIM PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 89:263-273.
46. ECKERT DM, MALASHKEVICH VN, HONG LH, CARR PA, KIM PS: Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell (1999) 99:103-115.
47. FERRER M, KAPOOR TM, STRASSMAIER T et al.: Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. (1999) 6:953-960.
48. ZHOU G, FERRER M, CHOPRA R et al: The structure of an HIV-1 specific cell entry inhibitor in complex with the HIV-1 gp41 trimeric core. Bioorg. Med. Chem. (2000) 8:2219-2227.
49. JIANG S, DEBNATH AK: A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity. Biochem. Biophys. Res. Commun. (2000) 270:153-157.
50. JIANG S, LU H, LIU S, ZHAO Q, HE Y, DEBNATH AK: N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. (2004) 48:4349-4359.
51. ERNST JT, KUTZKI O, DEBNATH AK, JIANG S, LU H, HAMILTON AD: Design of a protein surface antagonist based on α-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. Engl. (2002) 41:278-281.
52. DEBNATH AK, RADIGAN L, JIANG S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. (1999) 42:3203-3209.
53. JIANG S, LIN K, ZHANG L, DEBNATH AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods (1999) 80:85-96.
54. LIPINSKI CA: Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods (2000) 44:235-249.
55. ZHAO Q, ERNST JT, HAMILTON AD, DEBNATH AK, JIANG S: XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retrov. (2002) 18:989-997.
56. HANSCH C, LEO A, HOEKMAN D: Exploring QSAR Volume 2: Hydrophobic, electronic, and steric constants. American Chemical Society, Washington, DC, USA (1995).
57. HANSCH C, LEO A: Exploring QSAR fundamentals and applications in chemistry and biology. American Chemical Society, Washington, DC, USA (1995).
58. LIU S, LU H, ZHAO Q et al.: Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim. Biophys. Acta (2005) 1723:270-181.